Loading...
Exemestane potency is unchanged by common nonsynonymous polymorphisms in CYP19A1: results of a novel anti‐aromatase activity assay examining exemestane and its derivatives
Exemestane (EXE) treats estrogen receptor positive (ER+) breast cancer in postmenopausal women by inhibiting the estrogen‐synthesizing cytochrome P450 CYP19A1. Variability in the severity and incidence of side effects as well as overall drug efficacy may be partially explained by genetic factors, in...
Na minha lista:
| Udgivet i: | Pharmacol Res Perspect |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5464342/ https://ncbi.nlm.nih.gov/pubmed/28603632 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.313 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|